Central Nervous System Neoplasms

Inclusion Criteria

- Participant must be at least 18 years of age at the time of signing the informed consent. 
- Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of
the CNS. 
- Male and female. 
- Estimated glomerular filtration rate (eGFR) value ≥60 mL/min/1.73m^2.

Exclusion Criteria

- Considered clinically unstable. 
- Severe cardiovascular disease. 
- Any contraindication to MRI examinations. 
- History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents. 
- History of allergic asthma. 
- Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI: 
-- Meningeal disease (focal enhancement) 
-- Pituitary adenomas (macro and micro) 
-- Tumors of the choroid plexus 
-- Tumors of the pineal gland 
-- Dermoid/epidermoid tumors 
-- Infectious disease (e.g. brain abscess, cisticercosis, etc.) 
-- Venous angiomas 
-- Subacute/chronic ischemia 
-- Encephalitis 
-- Multiple sclerosis (acute and chronic) 
-- Optic neuritis 
-- Chordomas 
-- Von Hippel Lindau syndrome 
-- Hypertensive leukoencephalopathy. 
- Receipt of any contrast agent <72 h prior to the study MRIs, or planned receipt of any contrast agent within 72 h after the second study MRI. 
- Planned or expected biopsy or any interventional therapeutic procedure from the first study MRI up to 24 h after the second study MRI. - Planned or expected change in any treatment or procedure between the two study MRIs that may alter image comparability and /or chemotherapy which is changed between the two MRI procedures. 
- Contraindications to the administration of gadobutrol (depending on local product label).